Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04622319
Title A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Daiichi Sankyo, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | TUR | ROU | POL | NLD | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG


No variant requirements are available.